Organotypic models of patient-specific tumours are revolutionizing our understanding of
cancer heterogeneity and its implications for personalized medicine. These advancements …

The recent advances in in vitro 3D culture technologies, such as organoids, have opened
new avenues for the development of novel, more physiological human cancer models. Such …

Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer
biology and develop novel precision medicine therapeutics. However, utilizing TOs for …

Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that
stably retain key characteristics of the respective organs. Organoids can be generated from …

Organoid cultures have emerged as powerful model systems accelerating discoveries in
cellular and cancer biology. These three-dimensional cultures are amenable to diverse …

Cancer harbors variable heterogeneity and plasticity. Thus far, our comprehension is greatly
based on cell lines, organoids, and patient-derived tumor xenografts (PDTXs). Organoids …

Organoid technologies enable the creation of in vitro physiologic systems that model tissues
of origin more accurately than classical culture approaches. Seminal characteristics of these …

Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer
therapy. The ability to reconstruct intra-and interpatient heterogeneity in cancer models is …

Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient
basis with a high success rate. This creates opportunities to build large biobanks with …

Preclinical models of cancer are essential for a basic understanding of cancer biology and
its translation into efficient treatment options for affected patients. Cancer cell lines and …